Cancer Biomarker Detection by Surface Plasmon Resonance Biosensors

Clinics in Laboratory Medicine

Volumn 32, Issue 1, 2012, Pages 47-72

  Reddy, Panga Jaipal ^a   Sadhu, Sudipta ^a   Ray, Sandipan ^a   Srivastava, Sanjeeva ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Cancer biomarker; Cancer inhibitors; Protein microarray; SPR imaging; Surface plasmon resonance

Indexed keywords

2 (2,6 DIFLUOROPHENYL) 5 (4 METHOXY PHENYL) 1 OXA 3 AZASPIRO[5.5]UNDECANE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANTINEOPLASTIC AGENT; ATR PROTEIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CHECKPOINT KINASE RAD3; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; GLYPICAN 3; GOLD NANOPARTICLE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 8 ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 3; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN;

APOPTOSIS; BIOSENSOR; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DRUG TARGETING; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MOUTH CANCER; NONHUMAN; PANCREAS CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SURFACE PLASMON RESONANCE;

FEMALE; HUMANS; MALE; NEOPLASMS; PROTEIN ARRAY ANALYSIS; SURFACE PLASMON RESONANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84857065769     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2011.11.002     Document Type: Review

References (86)

1. Bensalah K., Montorsi F., Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 2007, 52:1601-1609.
2. Issaq H.J., Waybright T.J., Veenstra T.D. Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis 2011, 32:967-975.
3. Ray S., Reddy P.J., Jain R., et al. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11:2139-2161.
4. Kijanka G., Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics 2009, 72:936-944.
5. Drake R.R., Cazare L.H., Semmes O.J., et al. Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers. Expert Rev Mol Diagn 2005, 5:93-100.
6. Polanski M., Anderson N.L. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007, 1:1-48.
7. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
8. Omenn G.S. Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis Markers 2004, 20:131-134.
9. Wei B.R., Hoover S.B., Ross M.M., et al. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One 2009, 4:e7670.
10. Sun Y., Zang Z., Xu X., et al. Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophores and mass spectrometry. Int J Mol Sci 2010, 11:1423-1433.
11. Ramirez A.B., Loch C.M., Zhang Y., et al. Use of a single-chain antibody library for ovarian cancer biomarker discovery. Mol Cell Proteomics 2010, 9:1449-1460.
12. Wei-Jun Q., Jon M.J., Tao L., et al. Advances and challenges in liquid chromatography-mass spectrometry based proteomic profiling for clinical applications. Mol Cell Proteomics 2006, 5:1727-1744.
13. Miller J.C., Zhou H., Kwekel J., et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003, 3:56-63.
14. Jaras K., Ressine A., Nilsson E., et al. Reverse phase versus sandwich antibody microarray, technical comparison from a clinical perspective. Anal Chem 2007, 79:5817-5825.
15. Chandra H., Reddy P.J., Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011, 8:61-79.
16. Srivastava S., LaBaer J. Nanotubes light up protein arrays. Nat Biotechnol 2008, 26:1244-1246.
17. Ray S., Mehta G., Srivastava S. Label-free detection techniques for protein microarrays: prospects, merits and challenges. Proteomics 2010, 10:731-748.
18. Kawamoto S.A., Thompson A.D., Coleska A., et al. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. Biochemistry 2009, 48:9534-9541.
19. Jönsson U., Fägerstam L., Ivarsson B., et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 1991, 11:620-627.
20. Frasconi M., Tel-Vered R., Riskin M., et al. Surface plasmon resonance analysis of antibiotics using imprinted boronic acid-functionalized Au nanoparticle composites. Anal Chem 2010, 82:2512-2519.
21. Englebienne P., Hoonacker A.V., Verhas M. Surface plasmon resonance: principles, methods and applications in biomedical sciences. Spectroscopy 2003, 17:255-273.
22. Law W.C., Yong K.T., Baev A., et al. sensitivity improved surface plasmon resonance biosensor for cancer biomarker detection based on plasmonic enhancement. ACS Nano 2011, 5:4858-4864.
23. Halpern A.R., Chen Y., Corn R.M., et al. Surface plasmon resonance phase imaging measurements of patterned monolayers and DNA adsorption onto microarrays. Anal Chem 2011, 83:2801-2806.
24. Abbas A., Linman M.J., Cheng Q. New trends in instrumental design for surface plasmon resonance-based biosensors. Biosens Bioelectron 2011, 26:1815-1824.
25. Malic L., Sandros M.G., Tabrizian M. Designed biointerface using near-infrared quantum dots for ultrasensitive surface plasmon resonance imaging biosensors. AnalChem 2011, 83:5222-5229.
26. Steiner G. Surface plasmon resonance imaging. Anal Bioanal Chem 2004, 379:328-331.
27. Lausted C., Hu Z., Hood L. Quantitative serum proteomics from surface plasmon resonance imaging. Mol Cell Proteomics 2008, 7:2464-2474.
28. Yang C.Y., Brooks E., Li Y., et al. Detection of picomolar levels of interleukin-8 in human saliva by SPR. Lab Chip 2005, 5:1017-1023.
29. McCormick D.L., Phillips J.M., Horn T.L., et al. Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev Res (Phila) 2010, 3:73-81.
30. Kapoor V., Singh A.K., Dey S., et al. Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent. J Cancer Res Clin Oncol 2010, 136:1795-1804.
31. Patra C.R., Bhattacharya R., Mukhopadhyay D., et al. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010, 62:346-361.
32. Vaisocherová H., Faca V.M., Taylor A.D., et al. Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens Bioelectron 2009, 24:2143-2148.
33. Piliarik M., Bocková M., Homola J. Surface plasmon resonance biosensor for parallelized detection of protein biomarkers in diluted blood plasma. Biosens Bioelectron 2010, 26:1656-1661.
34. Choi J.W., Kang D.Y., Jang Y.H., et al. Ultra-sensitive surface plasmon resonance based immunosensor for prostate-specific antigen using gold nanoparticle-antibody complex. Colloids and Surfaces A: physicochem. Eng Aspects 2008, 313:655-659.
35. David N., Duyne R.V., Bingham J. Localized surface plasmon resonance nanobiosensors for the detection of a prostate cancer biomarker. Nanoscape 2008, 5:14-19.
36. Krishnan S., Mani V., Wasalathanthri D., et al. Attomolar detection of a cancer biomarker protein in serum by surface plasmon resonance using superparamagnetic particle labels. Angew Chem Int Ed Engl 2011, 50:1175-1178.
37. Nakano M., Nakagawa T., Ito T., et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008, 122:2301-2309.
38. Kazuno S., Fujimura T., Arai T., et al. Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. Anal Biochem 2011, 419:241-249.
39. Su F., Xu C., Taya M., et al. Detection of carcinoembryonic antigens using a surface plasmon resonance biosensor. Sensors 2008, 8:4282-4295.
40. Ladd J., Lu H., Taylor A.D., et al. Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces 2009, 70:1-6.
41. Ladd J., Taylor A.D., Piliarik M., et al. Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem 2009, 393:1157-1163.
42. Li Y., Lee H.J., Corn R.M. Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. Anal Chem 2007, 79:1082-1088.
43. Teramura Y., Iwata H. Label-free immunosensing for a-fetoprotein in human plasma using surface plasmon resonance. Anal Biochem 2007, 365:201-207.
44. Cho H.S., Ahn J.M., Han H.J., et al. Glypican 3 binds to GLUT1 and decreases glucose transport activity in hepatocellular carcinoma cells. J Cell Biochem 2010, 111:1252-1259.
45. Fang X., Tie J., Xie Y., et al. Detection of gastric carcinoma-associated antigen MG7-Ag in human sera using surface plasmon resonance sensor. Cancer Epidemiol 2010, 34:648-651.
46. Liu F., Zhang J., Den Y., et al. Detection of EGFR on living human gastric cancer BGC823 cells using surface plasmon resonance phase sensing. Sens Actuators B Chem 2011, 153:398-403.
47. Sariego J., Zrada S., Byrd M., et al. Breast cancer in the young patient. Am J Surg 2010, 76:1397-1400.
48. Carrascosa L.G., Calle A., Lechuga L.M. Label-free detection of DNA mutations by SPR: application to the early detection of inherited breast cancer. Anal Bioanal Chem 2009, 393:1173-1182.
49. Chang C.C., Chiu N.F., Lin D.S., et al. High-sensitivity detection of carbohydrate antigen 15-3 using a gold/zinc oxide thin film surface plasmon resonance-based biosensor. Anal Chem 2010, 82:1207-1212.
50. Myung J.H., Launiere C.A., Eddington D.T., et al. Enhanced tumor cell isolation by a biomimetic combination of E-selectin and anti-EpCAM: implications for the effective separation of circulating tumor cells (CTCs). Langmuir 2010, 26:8589-8596.
51. Lanati S., Dunn D.B., Roussigné M., et al. Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo. Cancer Res 2010, 70:8138-8148.
52. Khanna M., Chelladurai B., Gavini A., et al. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. Mol Cancer Ther 2011, 10:626-636.
53. Estrada A.C., Syrovets T., Pitterle K., et al. Tirucallic acids are novel pleckstrin homology domain-dependent akt inhibitors inducing apoptosis in prostate cancer cells. Mol Pharmacol 2010, 77:378-387.
54. Lang Q., Zhang H., Li J., et al. 3-Hydroxyflavone inhibits endogenous Aurora B and induces growth inhibition of cancer cell line. Mol Biol Rep 2010, 37:1577-1583.
55. Li L., Wang X., Chen J., et al. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Acta Pharmaco Sin 2009, 30:1443-1453.
56. Ma J.G., Huang H., Chen S.M., et al. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo. Breast Cancer Res Treat 2011, 130:85-96.
57. Yang J., Yu Y., Hamrick H.E., et al. ATM, ATRandDNA-PK:initiatorsofthecellulargenotoxicstress responses. Carcinogenesis 2003, 24:1571-1580.
58. Lu J.J., Cai Y.J., Ding J. Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells. Mol Cell Biochem 2011, 354:247-252.
59. Goldshmidt O., Zcharia E., Abramovitch R., et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 2002, 99:10031-10036.
60. Basappa N.S., Elson P., Golshayan A.R., et al. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer 2011, 117:1183-1189.
61. Olivier S., Robe P., Bours V. Can NF-kappaB be a target for novel and efficient anti-cancer agents?. Biochem Pharmacol 2006, 72:1054-1068.
62. Din F.V., Dunlop M.G., Stark L.A. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004, 91:381-388.
63. Ban J.O., Oh J.H., Hwang B.Y., et al. Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-κB activity via direct interaction with p50. Mol Cancer Ther 2009, 8:1613-1624.
64. Kim M.Y., Jeong S. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 2011, 21:173-178.
65. Macias A.T., Williamson D.S., Allen N., et al. Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity. J Med Chem 2011, 54:4034-4041.
66. Horibe T., Kohno M., Haramoto M., et al. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med 2011, 9:1-8.
67. Musso L., Dallavalle S., Merlini L., et al. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. Bioorg Med Chem 2010, 18:6031-6043.
68. Scarano S., Mascini M., Turner A.P., et al. Surface plasmon resonance imaging for affinity-based biosensors. Biosens Bioelectron 2010, 25:957-966.
69. Phillips K.S., Cheng Q. Recent advances in surface plasmon resonance based techniques for bioanalysis. Anal Bioanal Chem 2007, 387:1831-1840.
70. Linman M.J., Abbas A., Cheng Q. Interface design and multiplexed analysis with surface plasmon resonance (SPR) spectroscopy and SPR imaging. Analyst 2010, 135:2759-2767.
71. Singh A.K., Kant S., Parshad R., et al. Evaluation of human LOX-12 as a serum marker for breast cancer. Biochem Biophys Res Commun 2011, 414:304-308.
72. Jang H.S., Park K.N., Kang C.D., et al. Optical fiber SPR biosensor with sandwich assay for the detection of prostate specific antigen. Optics Comm 2009, 282:2827-2830.
73. Cao C., Kim J.P., Kim B.W., et al. A strategy for sensitivity and specificity enhancements in prostate specific antigen-1-antichymotrypsin detection based on surface plasmon resonance. Biosens Bioelectron 2006, 21:2106-2113.
74. Suwansa-ard S., Kanatharana P., Asawatreratanakul P., et al. Comparison of surface plasmon resonance and capacitive immunosensors for cancer antigen 125 detection in human serum samples. Biosens Bioelectron 2009, 24:3436-3441.
75. Mine N., Yamamoto S., Saito N., et al. CBP501-calmodulin binding contributes to sensitizing tumor cells to CDDP and BLM. Mol Cancer Therapy 2011, 10:1929-1938.
76. Ma J., Xin X., Meng L., et al. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. PLoS One 2008, 3:e3774.
77. Ahad A.M., Zuohe S., Du-Cuny L., et al. Development of sulfonamide AKT PH domain inhibitors. Bioorg Med Chem 2011, 19:2046-2054.
78. Vicari D., Foy K.C., Liotta E.M., et al. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011, 286:13612-13625.
79. Matthews S.B., Vielhauer G.A., Manthe C.A., et al. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 2010, 70:27-36.
80. Chang H.H., Song Z., Wisner L., et al. Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers. Invest New Drugs 2011, [Epub ahead of print].
81. Chen L., Pernazza D., Scott L.M., et al. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem Pharmacol 2010, 80:801-810.
82. Chen C.H., Kuo S.C., Huang L.J., et al. Affinity of synthetic peptide fragments of MyoD for Id1 protein and their biological effects in several cancer cells. J Pept Sci 2010, 16:231-241.
83. 3 with its inhibitors by SPR technology and molecular docking simulation. J Biomol Screen 2010, 15:131-137.
84. Qiu J., Xiao J., Han C., et al. Potentiation of tumor necrosis factor-α-induced tumor cell apoptosis by a small molecule inhibitor for anti-apoptotic protein hPEBP4. J Biol Chem 2010, 285:12241-12247.
85. Erkizan H.V., Scher L.J., Gamble S.E., et al. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle 2011, 10:3397-3408.
86. Bulut G., Hong S.H., Chen K., et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2011, [Epub ahead of print].